Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eisai Co. Ltd (OP: ESALF ) 43.85 -0.26 (-0.59%) Streaming Delayed Price Updated: 9:30 AM EDT, Jul 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Eisai Co. Ltd < Previous 1 2 3 Next > Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' July 15, 2024 Via Benzinga Topics Bankruptcy Exposures Financial Legal Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst July 03, 2024 The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... Via Benzinga Exposures Product Safety Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? June 11, 2024 Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... Via Benzinga Exposures Product Safety European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab March 22, 2024 Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. Via Benzinga Current Analysis: Eisai Co Ltd (ESAIY) July 16, 2023 Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price. Via Talk Markets Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer December 08, 2023 Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu Via Benzinga Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage October 13, 2023 The U.S. Via Benzinga LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly October 10, 2023 Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ: Via Benzinga Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories September 25, 2023 Benzinga Via Benzinga Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi September 25, 2023 Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be Via Benzinga Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer September 22, 2023 Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: Via Benzinga Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial August 25, 2023 Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck... Via Benzinga Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts July 07, 2023 The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... Via Benzinga Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources June 13, 2023 Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow Via Benzinga Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote June 12, 2023 Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria Via Benzinga Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' June 08, 2023 Senator Bernie Sanders urged the U.S. Via Benzinga FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval June 08, 2023 FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for... Via Benzinga Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen May 04, 2023 Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of Via Benzinga Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! April 21, 2023 Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... Via Benzinga Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer April 10, 2023 Via Benzinga National Institute on Aging Aims Building $300M Alzheimer's Research Database April 03, 2023 The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer... Via Benzinga Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug March 31, 2023 Via Benzinga Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments March 16, 2023 Via Benzinga Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity March 14, 2023 Via Benzinga Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment March 06, 2023 Via Benzinga The 7 Best Growth Stocks to Buy for February 2023 February 06, 2023 Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. Via InvestorPlace FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway January 06, 2023 Via Benzinga Biogen's Alzheimer's Antibody Might Have A Third Death Associated With December 22, 2022 A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. Via Benzinga Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug December 20, 2022 Via Benzinga Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate November 30, 2022 Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.